Evidence Hub

Acute Severe Pancolitis After Initiation of a Calcitonin Gene-Related Peptide Receptor Antagonist: A Case Report

Ravikulan A, Falvey J, Kubovy J

ACG case reports journal, 2026

Abstract

Calcitonin gene-related peptide receptor antagonists (CGRP-RA) are increasingly prescribed for migraine prophylaxis. Gastrointestinal side effects have been described, but association with inflammatory bowel disease (IBD) is reported rarely. A 50-year-old woman with well-controlled ulcerative proctitis developed a severe flare shortly after commencing a CGRP-RA (atogepant). She presented with abdominal pain and diarrhea. Investigations showed elevated inflammatory markers, predominantly right sided colitis on computer tomography scan, as well as endoscopic and histological evidence of severe pancolitis. Treatment with intravenous steroids was ineffective, but she responded to infliximab and discontinuation of the CGRP antagonist. She was well at follow-up 3 months later. CGRP-RA may can be associated with IBD relapse or de novo disease. We present a case of acute flare with change in phenotype of disease. Clinicians should exercise caution when prescribing CGRP-RA in patients with known IBD.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free